Sam-A Pharm. Co. Ltd

KQ:009300 Korea Pharmaceuticals
Market Cap
$67.40 Million
₩98.69 Billion KRW
Market Cap Rank
#25201 Global
#1533 in Korea
Share Price
₩16170.00
Change (1 day)
+1.32%
52-Week Range
₩15070.00 - ₩19050.00
All Time High
₩36150.00
Categories
Companies in Korea Pharmaceuticals
About

Sam-A Pharm. Co., Ltd operates as a pharmaceutical company in South Korea. The company offers a range of pharmaceutical products in the areas of respiratory, anti-biotics, anti-virals, anti-histamines, anti-fungals, dermatology, pain/inflammation, gastrointestinal, cardiovascular, metabolism, urological, and steroids, as well as psychotropic agents; and OTC products in the areas of respiratory, a… Read more

Sam-A Pharm. Co. Ltd (009300) - Net Assets

Latest net assets as of September 2025: ₩224.41 Billion KRW

Based on the latest financial reports, Sam-A Pharm. Co. Ltd (009300) has net assets worth ₩224.41 Billion KRW as of September 2025.

Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩246.13 Billion) and total liabilities (₩21.72 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.

Key Net Assets Metrics

Metric Value
Current Net Assets ₩224.41 Billion
% of Total Assets 91.18%
Annual Growth Rate 6.98%
5-Year Change 32.29%
10-Year Change 57.04%
Growth Volatility 6.44

Sam-A Pharm. Co. Ltd - Net Assets Trend (2009–2024)

This chart illustrates how Sam-A Pharm. Co. Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.

Annual Net Assets for Sam-A Pharm. Co. Ltd (2009–2024)

The table below shows the annual net assets of Sam-A Pharm. Co. Ltd from 2009 to 2024.

Year Net Assets Change
2024-12-31 ₩219.98 Billion +9.73%
2023-12-31 ₩200.47 Billion +10.99%
2022-12-31 ₩180.62 Billion +5.00%
2021-12-31 ₩172.02 Billion +3.45%
2020-12-31 ₩166.29 Billion -1.11%
2019-12-31 ₩168.15 Billion +4.50%
2018-12-31 ₩160.90 Billion +3.07%
2017-12-31 ₩156.10 Billion +4.83%
2016-12-31 ₩148.92 Billion +6.31%
2015-12-31 ₩140.08 Billion +4.42%
2014-12-31 ₩134.15 Billion +10.57%
2012-12-31 ₩121.33 Billion +9.72%
2011-12-31 ₩110.58 Billion +8.43%
2010-12-31 ₩101.99 Billion +27.62%
2009-12-31 ₩79.92 Billion --

Equity Component Analysis

This analysis shows how different components contribute to Sam-A Pharm. Co. Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have grown by 224.0% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (December 2024)

Component Amount Percentage
Retained Earnings ₩196.48 Billion 89.32%
Common Stock ₩6.37 Billion 2.90%
Other Components ₩17.12 Billion 7.78%
Total Equity ₩219.98 Billion 100.00%

Sam-A Pharm. Co. Ltd Competitors by Market Cap

The table below lists competitors of Sam-A Pharm. Co. Ltd ranked by their market capitalization.

Company Market Cap
W S Industries (I) Limited
NSE:WSI
 		$21.28 Million
Neonode Inc
NASDAQ:NEON
 		$21.28 Million
Jericho Oil Corp
PINK:JROOF
 		$21.28 Million
Arizona Lithium Limited
PINK:AZLAF
 		$21.29 Million
AJ Advance Technology Public Company Limited
BK:AJA
 		$21.27 Million
National Plastic Co Ltd Preferred
KO:004255
 		$21.26 Million
Shinih Enterprise Co Ltd
TW:9944
 		$21.26 Million
Air T Inc
NASDAQ:AIRT
 		$21.25 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Sam-A Pharm. Co. Ltd's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2023 to 2024, total equity changed from 200,470,212,490 to 219,975,767,580, a change of 19,505,555,090 (9.7%).
  • Net income of 22,079,574,400 contributed positively to equity growth.
  • Dividend payments of 4,577,506,500 reduced retained earnings.

Equity Change Factors (2023 to 2024)

Factor Impact Contribution
Net Income ₩22.08 Billion +10.04%
Dividends Paid ₩4.58 Billion -2.08%
Other Changes ₩2.00 Billion +0.91%
Total Change ₩- 9.73%

Book Value vs Market Value Analysis

This analysis compares Sam-A Pharm. Co. Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 0.45x
  • The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
  • The price-to-book ratio has decreased from 0.66x to 0.45x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
2016-12-31 ₩24399.17 ₩16170.00 x
2017-12-31 ₩25576.80 ₩16170.00 x
2018-12-31 ₩26363.09 ₩16170.00 x
2019-12-31 ₩27550.42 ₩16170.00 x
2020-12-31 ₩27245.21 ₩16170.00 x
2021-12-31 ₩28185.27 ₩16170.00 x
2022-12-31 ₩29593.29 ₩16170.00 x
2023-12-31 ₩32845.97 ₩16170.00 x
2024-12-31 ₩36041.87 ₩16170.00 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Sam-A Pharm. Co. Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): 10.04%
  • The company shows good efficiency in utilizing shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: 23.10%
  • • Asset Turnover: 0.38x
  • • Equity Multiplier: 1.13x
  • Recent ROE (10.04%) is above the historical average (7.20%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
2009 4.39% 6.60% 0.48x 1.39x ₩-4.49 Billion
2010 22.56% 42.03% 0.43x 1.26x ₩12.81 Billion
2011 8.88% 17.27% 0.41x 1.25x ₩-1.24 Billion
2012 9.85% 21.12% 0.39x 1.19x ₩-182.06 Million
2014 6.01% 14.21% 0.39x 1.09x ₩-5.35 Billion
2015 5.11% 12.00% 0.39x 1.09x ₩-6.85 Billion
2016 6.63% 14.98% 0.41x 1.09x ₩-5.02 Billion
2017 3.72% 9.39% 0.37x 1.08x ₩-9.81 Billion
2018 5.47% 13.15% 0.39x 1.08x ₩-7.29 Billion
2019 6.06% 14.25% 0.38x 1.13x ₩-6.62 Billion
2020 0.07% 0.23% 0.29x 1.10x ₩-16.50 Billion
2021 1.97% 6.20% 0.29x 1.10x ₩-13.81 Billion
2022 6.59% 14.58% 0.40x 1.13x ₩-6.15 Billion
2023 10.66% 21.99% 0.42x 1.15x ₩1.33 Billion
2024 10.04% 23.10% 0.38x 1.13x ₩82.00 Million

Industry Comparison

This section compares Sam-A Pharm. Co. Ltd's net assets metrics with peer companies in the Pharmaceuticals industry.

Industry Context

  • Industry: Pharmaceuticals
  • Average net assets among peers: $90,338,736,328
  • Average return on equity (ROE) among peers: -11.32%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Sam-A Pharm. Co. Ltd (009300) ₩224.41 Billion 4.39% 0.10x $21.27 Million
Sam Chun Dang Pharm. Co. Ltd (000250) $114.32 Billion 10.17% 0.61x $3.69 Billion
DongKoo Bio&Pharma Co. Ltd (006620) $94.65 Billion 9.66% 0.53x $57.77 Million
NatureCell Co.Ltd (007390) $34.02 Billion -9.48% 0.55x $37.82 Million
Kyung Dong Pharmaceutical Co. Ltd (011040) $257.20 Billion 4.73% 0.21x $50.06 Million
WooGene B&G Co. Ltd (018620) $26.51 Billion -25.02% 1.26x $10.61 Million
Oscotec Inc (039200) $28.83 Billion -91.10% 0.70x $890.75 Million
EstechPharma Co. Ltd (041910) $123.30 Billion 5.58% 0.09x $50.99 Million
Komipharm International Co. Ltd (041960) $93.39 Billion -15.32% 0.50x $237.27 Million
Eagle Veterinary Technology Co.Ltd (044960) $40.83 Billion 8.91% 0.29x $20.48 Million